Benjamin A. Schiffman

Array ( [id] => 16612192 [patent_doc_number] => 20210030845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => VASOINTESTINAL PEPTIDE RECEPTOR INHIBITORS FOR ENHANCEMENT OF GASTROINTESTINAL HEALTH [patent_app_type] => utility [patent_app_number] => 16/943610 [patent_app_country] => US [patent_app_date] => 2020-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16943610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16583205 [patent_doc_number] => 20210017607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => Methods of Predicting Responsiveness to Cancer Therapies [patent_app_type] => utility [patent_app_number] => 16/933885 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31440 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16933885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19595219 [patent_doc_number] => 12153056 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-26 [patent_title] => Compositions for and methods of diagnosing, prognosing, and treating diabetes [patent_app_type] => utility [patent_app_number] => 16/929411 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 15340 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17882778 [patent_doc_number] => 20220298255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => E-CADHERIN ACTIVATING ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/608886 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34546 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685903 [patent_doc_number] => 20220193195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => LYMPHOTOXIN ALPHA FOR USE IN THERAPY OF MYELOID LEUKEMIA [patent_app_type] => utility [patent_app_number] => 17/608446 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720786 [patent_doc_number] => 20220213506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => EXPRESSION OF ANTIGEN-BINDING PROTEINS IN THE NERVOUS SYSTEM [patent_app_type] => utility [patent_app_number] => 17/611849 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10835 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17611849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733379 [patent_doc_number] => 20220218838 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => ADC FOR A TREATMENT CONCOMITANT WITH OR SUBSEQUENT TO DOCETAXEL [patent_app_type] => utility [patent_app_number] => 17/609129 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17705974 [patent_doc_number] => 20220205980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => BIOMARKER FOR RHEUMATOID ARTHRITIS TREATMENT [patent_app_type] => utility [patent_app_number] => 17/601908 [patent_app_country] => US [patent_app_date] => 2020-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17601908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685736 [patent_doc_number] => 20220193028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => THERAPEUTIC COMBINATIONS, LIQUID PHARMACEUTICAL COMPOSITIONS, KITS FOR THEIR PREPARATION, AND METHODS OF THEIR USE [patent_app_type] => utility [patent_app_number] => 17/603707 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17603707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761516 [patent_doc_number] => 20220235128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => ANTI-CLDN ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND DETECTION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 17/611370 [patent_app_country] => US [patent_app_date] => 2020-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17611370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655279 [patent_doc_number] => 20220175744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => COMBINATIONS OF TRANSCRIPTION INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF DISEASE [patent_app_type] => utility [patent_app_number] => 17/600600 [patent_app_country] => US [patent_app_date] => 2020-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655420 [patent_doc_number] => 20220175885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => TARGETING BIOLOGICAL AGENTS TO MUCOSAL DEFECTS OF THE GASTROINTESTINAL TRACT [patent_app_type] => utility [patent_app_number] => 17/439339 [patent_app_country] => US [patent_app_date] => 2020-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611555 [patent_doc_number] => 20220153834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => TSG-6 ANTIBODIES AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 17/434368 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611549 [patent_doc_number] => 20220153828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => Methods for Treating TNFa-Related Diseases [patent_app_type] => utility [patent_app_number] => 17/430628 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17549391 [patent_doc_number] => 20220120732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => TREATMENT OF DISEASES WITH MULTIMERIC PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/428714 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17428714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441878 [patent_doc_number] => 20220062383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => REGULATION OF A FOREIGN BODY RESPONSE [patent_app_type] => utility [patent_app_number] => 17/423043 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21248 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18910368 [patent_doc_number] => 11873338 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease [patent_app_type] => utility [patent_app_number] => 17/294338 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 44 [patent_no_of_words] => 28206 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370016 [patent_doc_number] => 20220025068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ANTI SUPEROXIDE DISMUTASE 1 (SOD1) ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/297167 [patent_app_country] => US [patent_app_date] => 2019-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20386616 [patent_doc_number] => 12486333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Tissue plasminogen activator antibodies and method of use thereof [patent_app_type] => utility [patent_app_number] => 17/292883 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 46 [patent_no_of_words] => 16846 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336065 [patent_doc_number] => 20220002396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/290157 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -87 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290157 [rel_patent_id] =>[rel_patent_doc_number] =>)